(Q33428575)

English

Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

peripheral T-cell lymphoma

1 reference

based on heuristic

inferred from title

William Ying Khee Hwang

3

object named as

William Y K Hwang

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Daryl Tan

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Colin Phipps

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Soo Yong Tan

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chun Hsien Yeap

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yiong Huak Chan

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kevin Tay

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Soon Thye Lim

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yuh Shan Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sathish Gopalakrishnan Kumar

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Soo Chin Ng

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Fadilah

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Won Seog Kim

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yeow Tee Goh

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

SGH651 Investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

7 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The Lancet. Haematology.

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

e326-33

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900097-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3026(15)00097-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33428575&oldid=1536246017"